Transgene announced the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately. Dr. Wentworth will be responsible for developing, leading, and implementing Transgene?s business, corporate development and partnering strategies. Dr. Wentworth brings over fifteen years?

experience working in the pharma and biotech industry. He joins Transgene following increasing responsibility spanning business development, strategy and commercial roles. Most recently, James was Director, Business Development and Strategy at Adaptimmune.

His responsibilities included strategic pharma partnering, collaborations and transactions, corporate development projects, commercial strategy development and he also led the company?s competitive intelligence function. Prior to Adaptimmune, James worked with pre-commercial Biotech companies at inVentiv Health (now Syneos Health) and held strategic roles at Shire, contributing to product development, post M&A integration, and managing commercial launches in European markets for ViroPharma Europe. James holds a BSc Hons degree in Pharmacology and a PhD in Pharmacology both from the University of Bristol and an MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland.